Please login to the form below
CAR-Ts
This page shows the latest CAR-Ts news and features for those working in and with pharma, biotech and healthcare.
CAR-Ts take centre stage as ASH18 comes to a close
to administer therapy that doesn’t require the process of harvesting, modifying and re-infusing cells needed with autologous CAR-Ts. ... what some commentators think is a reason (alongside price and reimbursement) for sluggish uptake of
Latest news
-
Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma
There were signs of efficacy with AMG 420 even at a lower dose of 200µg/day, but the big question now is whether off-the-shelf drugs will match CAR-Ts ... treated in trials of Bluebird’s CAR-Ts had seven or more, with a might higher proportion of the
-
ASH18: CAR-T and drugs give new options for multiple myeloma
earlier timepoint, and Celgene is due to report results on no fewer than three anti-BCMA CAR-Ts developed by Juno – namely JCARH125, MCARH171 and FCARH143. ... five complete responses in five patients – that could pose a threat to the BCMA-targeting
-
Regeneron’s early stage bispecific shows promise
Bispecifics and antibody drug conjugates will challenge CAR-Ts. The potentially revolutionary nature of CAR-Ts has made them the hottest properties in haemato-oncology in recent years, but a wave ... This approach could see them match the clinical
-
Celgene to launch five new products through to 2020
myelofibrosis, thalassaemia therapy luspatercept, and CAR-T candidates lisocabtagene maraleucel (liso-cel) for lymphoma and bb2121 for multiple myeloma. ... The two CAR-Ts could be approved in 2020, while the other three candidates are due to be
-
Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts
Arie Belldegrun (left) and David Cheng . Belldegrun and Cheng they can go one better than these first generation autologous CAR-Ts. ... Allogene is among a number of companies who want to leapfrog the leaders with allogenic or 'off the shelf' CAR-Ts.
More from news
Approximately 8 fully matching, plus 15 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
FITC, which is not naturally present in the body, then becomes the target for CAR‐Ts expressing high affinity for FITC. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
therapies, such as CAR-Ts Kymriah and Yescarta.
-
Cancer immunotherapy: What's on the horizon?
antigen receptor T-cell (CAR-T) therapies from Novartis and Gilead gained regulatory approval in 2017 for acute lymphoblastic leukaemia (ALL) and diffuse large B-cell lymphoma (DLBCL) after showing remarkable ... The CAR-Ts have transformed the treatment
-
Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?
It follows that the next generation of relationship holders, representing very expensive but ultra-personalised medicines like CAR-Ts (which are based on patients’ own cells) will be concierge-like, offering
-
Bluebird Bio: on the cusp of a gene therapy revolution
Analysts think bb2121 could gain approval by 2020 and hit peak sales of $5bn, leading a crowded CAR-T field in the disease. ... This is especially likely around its multiple myeloma candidate bb2121, where competition will be fierce from rival multiple
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Featured jobs
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
-
Associate Director
-
£75, 000-90, 000
-
Account Manager / Account Director
-
Competative
-
Business Director
-
Competitive Salary Offered
- Business Development Director – Health Education
-
excellent commission
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
-
Medical (Scientific) Director
-
£120, 000 benefits
- Principal Health Economist - North-West
-
Negotiable
-
Account Director
-
Competitive Salary Offered
- Account Manager- Healthcare Advertising
-
Negotiable
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Account Manager
-
Negotiable
-
Systematic Reviewer - Oxford
-
Negotiable
Subscribe to our email news alerts
- FDA clears Sandoz and Pear’s Opioid Use Disorder app
- As May delays, industry warns again of ‘no-deal’ Brexit
- Clark Health Communications and Egg digital announce new collaboration
- Axovant drops last ‘legacy’ drug to focus on gene therapies
- Healthcare excellence celebrated at 2018 HSJ Awards
- Better together when buying medicines? Taking stock of the BeNeLuxA initiative
PMHub
Frontera Group
Welcome to Frontera Group where our agencies immerse you into the world of the patient....
Latest intelligence
- Report: Achieving launch excellence in the challenging healthcare markets of today
- Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
- What is blockchain and why should i care - Richard Springham
- Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
- NHS medicines optimisation milestone
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Quick links
Infographics
